Abstract
Lung cancer deaths exceed the combined mortality from breast, prostate, and colorectal cancers (1). Every year more than 150,000 Americans die from this deadly disease. Lung carcinoma classes include small cell lung carcinomas (SCLC) and nonsmall cell lung carcinomas (NSCLC). The distinction of SCLC from NSCLC is important as the clinical course and treatments for the two diseases are different. SCLC patients initially respond well to chemotherapy, followed by regression of the tumor. However, in most cases, the patient relapses, develops chemoresistance, and eventually dies from systemic dissemination of cancer. In contrast, in early stage NSCLC disease, treatment involves surgical removal of primary tumor (resection). However, 50% of those patients undergo relapse and eventually die from metastasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
